Quality Pharmaceutical Service: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Quality Pharmaceutical Service
Largest movements
- Cash +€38,181
up €38,181 (+112%), from €34,175 to €72,356
mainly Net result for the year (+€45,114) and Tax, wage and social debts (+€15,936)
- Receivables within one year +€17,566
up €17,566 (+123%), from €14,298 to €31,865
of which Other amounts receivable: +€15,555
- Tangible fixed assets +€2,914
new in 2025: €2,914
- Deferred charges and accrued income +€2,389
up €2,389 (+397%), from €602 to €2,990
- Profit (loss) carried forward +€45,114
up €45,114 (+138%), from €32,782 to €77,895
- Tax, wage and social debts +€15,936
up €15,936 (+120%), from €13,293 to €29,229
- Gross operating margin +€18,800
up €18,800 (+45.8%), from €41,032 to €59,832
- Taxes +€7,025
up €7,025 (+85.2%), from €8,248 to €15,273
- Financial income +€679
new in 2025: €679
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €49,074 | €110,124 | +€61,050 | +124% |
| Fixed assets | 21/28 | - | €2,914 | +€2,914 | |
| Tangible fixed assets | 22/27 | - | €2,914 | +€2,914 | |
| Furniture and vehicles | 24 | - | €2,914 | +€2,914 | |
| Current assets | 29/58 | €49,074 | €107,210 | +€58,136 | +118% |
| Amounts receivable within one year | 40/41 | €14,298 | €31,865 | +€17,566 | +123% |
| Trade receivables | 40 | €9,533 | €11,544 | +€2,011 | +21.1% |
| Other amounts receivable | 41 | €4,765 | €20,321 | +€15,555 | +326% |
| Cash at bank and in hand | 54/58 | €34,175 | €72,356 | +€38,181 | +112% |
| Deferred charges and accrued income | 490/1 | €602 | €2,990 | +€2,389 | +397% |
| Total equity and liabilities | 10/49 | €49,074 | €110,124 | +€61,050 | +124% |
| Equity | 10/15 | €35,782 | €80,895 | +€45,114 | +126% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €32,782 | €77,895 | +€45,114 | +138% |
| Amounts payable | 17/49 | €13,293 | €29,229 | +€15,936 | +120% |
| Amounts payable within one year | 42/48 | €13,293 | €29,229 | +€15,936 | +120% |
| Taxes, remuneration and social security | 45 | €13,293 | €29,229 | +€15,936 | +120% |
| Taxes | 450/3 | €13,293 | €29,229 | +€15,936 | +120% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | - | €125 | +€125 | |
| Gross operating margin | 9900 | €41,032 | €59,832 | +€18,800 | +45.8% |
| Operating profit (loss) | 9901 | €41,032 | €59,707 | +€18,675 | +45.5% |
| Financial income | 75/76B | - | €679 | +€679 | |
| Recurring financial income | 75 | - | €679 | +€679 | |
| Financial charges | 65/66B | €3 | - | -€3 | |
| Recurring financial charges | 65 | €3 | - | -€3 | |
| Profit (loss) for the period before taxes | 9903 | €41,030 | €60,386 | +€19,357 | +47.2% |
| Income taxes | 67/77 | €8,248 | €15,273 | +€7,025 | +85.2% |
| Profit (loss) for the period | 9904 | €32,782 | €45,114 | +€12,332 | +37.6% |
| Profit (loss) for the period to be appropriated | 9905 | €32,782 | €45,114 | +€12,332 | +37.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 27 October 2026 via checked.be.